Roche's Phesgo Could Reduce Healthcare Costs In EU
Other EU Year-End Approvals In Peanut Allergies, HIV/AIDS
Executive Summary
Roche’s Phesgo may lower healthcare costs in Europe for treating breast cancer following its approval by European Commission. Other just-approved products nearing the EU market are ViiV’s Vocabria, to be used with Janssen’s Rekambys/Edurant, as a long-acting injectable HIV therapy, and Aimmune’s peanut allergy therapy, Palforzia.
You may also be interested in...
Tough Q3 For Roche But Diagnostics Soften The Blow
The Swiss major's old guard of oncology products continue to falter but Roche's new wave of treatments is helping to keep the financials fairly healthy.
Nestle, Bullish On Palforzia, To Buy Remainder Of Aimmune
Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.
FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen
ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.